Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Naltrexone may fight breast cancer by blocking the use of estrogen by the tumor cells. Naltrexone may also stop the growth of breast cancer by impairing blood flow to the tumor. PURPOSE: This phase II trial is studying how well naltrexone works in treating women with metastatic breast cancer that is no longer responsive to previous hormone therapy.

Timeline

Start

2006-07

Primary completion

2013-05

Completion

2013-05

Publications

• Vijayakumar J, Haddad T, Gupta K, Sauers J, Yee D. An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer. Invest New Drugs. 2023 Feb;41(1):70-75. doi: 10.1007/s10637-022-01317-4. Epub 2022 Nov 28.

Drugs

Indications